Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has 7 years of Operating Leases data on file, last reported at $24.0 million in Q4 2025.

• Operating Leases for Q4 2025 came in at $24.0 million, down 20.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $24.0 million (down 20.0% YoY), and the FY2025 annual result was $24.0 million, down 20.0% from the prior year.
• Operating Leases grew to $24.0 million in Q4 2025 per RARE's latest filing, from $21.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $36.8 million in Q1 2021 and troughed at $14.8 million in Q2 2023.
• A 5-year average of $26.8 million and a median of $26.8 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2024: Operating Leases sank 42.69% in 2023, then jumped 73.4% in 2024.
• A 5-year view of Operating Leases shows it stood at $30.9 million in 2021, then plunged by 35.89% to $19.8 million in 2022, then soared by 54.31% to $30.6 million in 2023, then dropped by 1.88% to $30.0 million in 2024, then decreased by 20.0% to $24.0 million in 2025.
• Business Quant data shows RARE's Operating Leases at $24.0 million in Q4 2025, $21.7 million in Q3 2025, and $24.5 million in Q2 2025.